

****New release October 2012****

MarketVIEW: Hepatitis A vaccines (travel) (CAT: VAMV029B)

Product Name	:	MarketVIEW: Hepatitis A vaccines (Travel)
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast model
Therapeutic Area	:	Pediatric/adults vaccines
Publication date	:	October 2012
Catalogue No	:	VAMV029B

Background

Hepatitis A (HAV) produces a self-limiting liver disease which can produce a range of symptoms such as nausea, anorexia, fever, malaise or abdominal pain. Unlike Hepatitis B and C viruses it does not cause a long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to due ingestion of contaminated food. Many countries in Africa, LATAM and SE Asia have high or intermediate endemicity for HAV.

The Hepatitis A vaccine is highly effective at preventing HAV infection and is now recommended for all children at age 1 year in the United States and other selected countries which have added the vaccine as part of a national immunization program (NIP). The HAV vaccine is also widely used in the travelling population to high or intermediate endemic countries.

This **MarketVIEW** product is a comprehensive commercial opportunity assessment which forecasts the potential (value/volume) of monovalent HAV vaccines in the travelling population from EU, North America and selected ROWD countries of origin. The model uses a "build up" methodology based upon number of trips to HAV endemic countries forecasted to 2030. It is designed to compliment other **VacZine Analytics** analyses focused on HAV vaccines.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to hepatitis A virus epidemiology/vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of pediatric vaccines has also been utilised. *****See Bibliography for exact sources.**

PRODUCT CONTENTS:

Published October 2012 (CAT No: VAMV029B)

****This product is composed a forecast model and an Executive presentation

Contents – Executive presentation (MS PowerPoint based)

Authors Note
Executive summary
Commercial model: key outputs
Travelers: countries of origin selected for HAV model
Countries considered HAV infection risk to travelers
Trips to HAV endemic regions (2011)
Forecast number of Trips to HAV endemic regions to 2030
Monovalent HAV vaccines*: est travel volumes per region
Monovalent HAV vaccines*: est travel volumes per EU countries
Monovalent HAV vaccines*: est travel revenues per region
Monovalent HAV vaccines*: est travel revenues per EU country
Commercial model: Travelers – detailed assumptions
HAV travelers segment: overview of modeling strategy
Model assumptions: - North American markets
Model assumptions: - European markets
Model assumptions: - ROWD markets
HAV travelers segment: pricing assumptions
Major model caveats and limitations
Back-up/source material
HAV vaccines: schedule considerations for travelers segment
Example penetration rates of travel vaccines
Benchmarking HAV travel market estimation
Hepatitis vaccines: company reported sales
Bibliography
Disclaimer
About **VacZine Analytics**

PAGES: 30 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based)

Title sheet
Chart – value
Chart – volume
Grand val/vol summary
EU value summary
North America value summary
ROWD value summary
Monoval – prices (ex fact)
EU volume summary
North America volume summary
ROWD volume summary
Country worksheets =>>
EU markets =>
UK travelers
France travelers
Germany travelers
Italy travelers
Spain travelers
Denmark travelers
Finland travelers
Norway travelers
Sweden travelers
UK travelers
North America markets
US travelers =>
Canada travelers
ROWD markets =>
Australia travelers
Brazil travelers
South Korea travelers
Souce material =>
Trips to HAV endemic countries
HAV endemic countries
Trips CHARTS
VA travel data
Travel planning and duration
Travel market sizes
Travel vaccine penetration rates
US prices
Hepatitis vaccine sales
Back page

WORKSHEETS = 40

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$5995.00/ GBP £3745.00[#] (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

indicative only rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according to the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009